Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | F10 | P00742 | 11/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009168 | 0.91 | MAPT (0.57) | NPC1RAB9AF10SMN1; SMN2KMT2A | |
| SCHEMBL14009155 | 0.90 | L3MBTL1 (0.60) | NPC1RAB9AF10KMT2ATP53 | |
| SCHEMBL14009225 | 0.89 | MAPKAPK2 (0.53) | NPC1RAB9AF10SMN1; SMN2KMT2A | |
| SCHEMBL14009158 | 0.80 | NPC1 (0.54) | NPC1RAB9AF10SMN1; SMN2KMT2A | |
| SCHEMBL14009231 | 0.79 | MAPT (0.52) | NPC1RAB9AF10SMN1; SMN2KMT2A | |
| SCHEMBL14009284 | 0.79 | CA1 (0.50) | NPC1RAB9AF10SMN1; SMN2KMT2A | |
| SCHEMBL14009015 | 0.78 | MAPT (0.46) | NPC1RAB9AF10SMN1; SMN2KMT2A | |
| SCHEMBL14009187 | 0.78 | MEN1 (0.48) | F10SMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL14009026 | 0.78 | RAB9A (0.46) | NPC1RAB9AF10SMN1; SMN2 | |
| SCHEMBL14009222 | 0.78 | RXFP1 (0.51) | NPC1RAB9AF10SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | NPC1 4547/4885RAB9A 3846/4885F10 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.